Display Settings:

Format

Send to:

Choose Destination

    Diabetes. 2008 Sep;57(9):2332-40. Epub 2008 Jun 20.

    Cholinergic regulation of ghrelin and peptide YY release may be impaired in obesity.

    Maier C, Riedl M, Vila G, Nowotny P, Wolzt M, Clodi M, Ludvik B, Luger A.

    Clinical Division of Endocrinology and Metabolism, Department ofMedicine III, Medical University of Vienna, Vienna, Austria. christina.maier@meduniwien.ac.at

    OBJECTIVE: Ghrelin and peptide YY (PYY) are both hormones derived from the gastrointestinal tract involved in appetite regulation. The cholinergic part of the vagal nerve is involved in the regulation of glucose and insulin. The aim of this study was to examine the effects of the cholinergic antagonist atropine on ghrelin, PYY, glucose, and insulin under basal conditions and after meal ingestion in lean and obese subjects. RESEARCH DESIGN AND METHODS: Eight lean and eight obese subjects were included in a randomized, double-blind, placebo-controlled crossover study with 4 study days in randomized order (atropine/placebo +/- breakfast). Plasma ghrelin, PYY, insulin, and glucose were measured. Hunger and satiety feelings were rated on a 10-cm visual analog scale. RESULTS: In lean individuals, atropine led to a decrease in ghrelin concentrations comparable and nonadditive with breakfast ingestion and a significant decrease in both basal and meal-induced PYY concentrations. In obese subjects, atropine did not significantly change ghrelin or PYY concentrations, whereas it induced a comparable increase in heart rate and meal-induced glucose concentrations in the two study groups. Only lean, not obese, subjects experienced sustained feelings of satiety after breakfast. CONCLUSIONS: The impaired cholinergic regulation of the postprandial drop in ghrelin concentrations and rise in PYY concentrations might be part of the deregulated food intake in obese subjects.

    PMID: 18567824 [PubMed - indexed for MEDLINE]

    PMCID: 2518484

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Hyoscyamine (Anaspaz®, Cystospaz®, Cystospaz-M®, ...)

      Hyoscyamine is used to control symptoms associated with disorders of the gastrointestinal (GI) tract. It works by decreasing the motion of the stomach and intestines and the secretion of stomach fluids, including acid. H...